1995
Medical Eligibility, Comprehension of the Consent Process, and Retention of Injection Drug Users Recruited for an HIV Vaccine Trial
Harrison K, Vlahov D, Jones K, Charron K, Clements M. Medical Eligibility, Comprehension of the Consent Process, and Retention of Injection Drug Users Recruited for an HIV Vaccine Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1995, 10: 386-390. PMID: 7552502, DOI: 10.1097/00042560-199511000-00012.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS VaccinesClinical Trials as TopicComprehensionConsent FormsDouble-Blind MethodEducational StatusEligibility DeterminationFemaleHIV InfectionsHumansInformed ConsentMaleMiddle AgedPatient SelectionResearch DesignResearch SubjectsSubstance Abuse, IntravenousSurveys and QuestionnairesConceptsInjection drug usersHIV vaccine trialsVaccine trialsDrug usersHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionPhase II trialInformed consent procedureConsent proceduresII trialVirus infectionHigh riskMedical reasonsMedical eligibilityTrialsConsent processEnrollmentFollowInfectionFalse testVisitsInterest in HIV Vaccines Among Italian Injection Drug Users
Serpelloni G, Vlahov D, Mazzi M, Rezza G. Interest in HIV Vaccines Among Italian Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1995, 10: 206-207. PMID: 7552488, DOI: 10.1097/00042560-199510020-00016.Peer-Reviewed Original Research
1994
Preparations for AIDS vaccine trials. Incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland.
Nelson K, Vlahov D, Galai N, Astemborski J, Solomon L. Preparations for AIDS vaccine trials. Incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland. AIDS Research And Human Retroviruses 1994, 10 Suppl 2: s201-5. PMID: 7865301.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV incidenceIncident human immunodeficiency virus (HIV) infectionsDrug usersHIV vaccine trial participationHuman immunodeficiency virus (HIV) infectionRisk behaviorsCohort of IDUsHuman immunodeficiency virus (HIV) vaccinesHIV-seronegative subjectsHigh HIV incidenceImmunodeficiency virus infectionAIDS vaccine trialsVaccine trial participationImmunodeficiency virus vaccinesHigh-risk behaviorsHIV seroconversionAnnual incidenceHIV vaccineNeedle sharingTrial participationVaccine trialsVirus vaccineVirus infectionStudy subjectsInterest in HIV vaccines among injection drug users in Baltimore, Maryland.
Vlahov D, Astemborski J, Solomon L, Galai N, Basarab L, Nelson K. Interest in HIV vaccines among injection drug users in Baltimore, Maryland. AIDS Research And Human Retroviruses 1994, 10 Suppl 2: s265-8. PMID: 7865315.Peer-Reviewed Original ResearchHIV vaccines for injection drug users in the context of a comprehensive prevention agenda.
Vlahov D. HIV vaccines for injection drug users in the context of a comprehensive prevention agenda. AIDS Research And Human Retroviruses 1994, 10 Suppl 2: s3-6. PMID: 7865324.Peer-Reviewed Original ResearchConceptsHIV infectionHIV vaccineDrug usersHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionEffective HIV vaccineInjection drug usersMajor health problemNeedle exchange programsHigh-risk behaviorsParenteral transmissionVirus infectionHealth problemsDrug abusePrevention agendaInfectionRisk reductionVaccineHIVPopulationAbstinenceExchange programs
1991
Antibody Responses to Haemophilus influenzae Type b Vaccines in Men with Human Immunodeficiency Virus Infection
Steinhoff M, Auerbach B, Nelson K, Vlahov D, Becker R, Graham N, Schwartz D, Lucas A, Chaisson R. Antibody Responses to Haemophilus influenzae Type b Vaccines in Men with Human Immunodeficiency Virus Infection. New England Journal Of Medicine 1991, 325: 1837-1842. PMID: 1683682, DOI: 10.1056/nejm199112263252603.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionInfluenzae type b vaccineAsymptomatic HIV infectionImmunodeficiency virus infectionSymptomatic HIV infectionType b vaccineHIV infectionAntibody responsePRP vaccineB vaccineVirus infectionH. influenzae type b vaccineHaemophilus influenzae type b vaccineType b polysaccharide vaccineGeometric mean antibody titersHIV-seropositive menPRP antibody titersPutative protective levelGreater antibody responseH. influenzae type b.Mean antibody titersSeronegative subjectsCD4 lymphocytesPolysaccharide vaccineSeronegative men